The U.S. Food and Drug Administration has approved a highly effective HIV prevention drug that outperforms oral medications in stopping HIV transmission. Developed by Gilead Sciences, the drug ...

Thanks to PrEP drugs, a country without HIV was in reach. That's now at risk.

Add Yahoo as a preferred source to see more of our stories on Google. This acquisition marks Gilead's first entry into the field of T-cell engagers. Credit: Tada Images / Shutterstock.com. (Tada ...

The Centers for Medicare & Medicaid Services (CMS) is recommending preexposure prophylaxis (PrEP) with oral or injectable antiretroviral therapy to people at risk of HIV without patient cost sharing.

It’s been over a decade since the Food and Drug Administration first approved a medication to prevent HIV. But the Centers for Disease Control and Prevention estimates just 30% of the 1.2 million ...

It’s possible to produce a generic version of lenacapavir, a twice-yearly antiretroviral injection that both prevents and treats HIV, for as little as $25 per patient per year, according to a study ...

US Sen. Kamala Harris is introducing a bill to reduce the transmission of HIV by encouraging the use of PrEP, or pre-exposure prophylaxis, a drug that's more than 92% effective in preventing new ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Gilead's CEO earlier this year ...

When Dr. Sharon Nachman treats teenagers or young adults, she often asks about their sexual health and whether they would consider a medication that can vastly improve the chances of avoiding an HIV ...

After nearly a decade of working as an advocate for HIV and AIDS treatment, Michael Chancley said he came to a sobering realization. “Seeing that people who look like me, who hang out at the same ...

HIV rates are up in Atlanta. Activists and Georgia politicians say this doesn’t have to happen because cheap and safe medicines known as PrEP are over 99% effective at blocking the infection when ...

Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for HIV, offering patients a twice-yearly injection to reduce the risk of ...